On the one hand, molecular analysis takes a preponderant place in the BCR::ABL1-negative MPN diagnosis and on the other hand, the bone marrow (BM) biopsy becomes nearly mandatory as a part of BCR::ABL1-negative MPN diagnosis to avoid missing out. This evidence concerns the gene ABL1 and myeloproliferative disorder.